Abstract

Chronic liver disease represents stepwise destruction of the liver parenchyma after chronic liver injury, which is often difficult to be diagnosed accurately. Thus, the development of specific biomarkers of chronic liver disease is important. Metabolomics is a powerful tool for biomarker exploration, which enables the exploration of disease pathogenesis or drug action mechanisms at the global metabolic level. The metabolomics workflow generally includes collection, preparation, and analysis of samples, and data processing and bioinformatics. A metabolomics study can simultaneously detect the dysfunctions in the glucose, lipid, amino-acid, and nucleotide metabolisms. Hence, it facilitates the obtaining of a better understanding of the pathogenesis of chronic liver disease and its diagnosis. Many effective drugs could reverse the change of comprehensive biochemical phenotypes induced by chronic liver disease. They can even potentially restore the normal metabolic signatures of patients. Increasingly more researchers have begun to apply metabolomics technologies to diagnose chronic liver disease and investigate the mechanism of action of effective drugs or the variations in drug responses. We are convinced that deepening the understanding of the metabolic alterations could extend their use as powerful biomarkers, promoting the more effective clinical diagnosis and treatment of chronic liver disease in the future.

摘要

慢性肝病是指慢性肝损伤后肝实质的逐步破坏，往往难以准确诊断。因此，开发慢性肝病的特异性生物标志物很重要。代谢组学是生物标志物探索的有力工具，可以在全球代谢水平上探索疾病发病机制或药物作用机制。代谢组学工作流程通常包括样品的收集、制备和分析，以及数据处理和生物信息学。代谢组学研究可以同时检测葡萄糖、脂质、氨基酸和核苷酸代谢中的功能障碍。因此，它有助于更​​好地了解慢性肝病的发病机制及其诊断。许多有效的药物可以逆转慢性肝病引起的综合生化表型变化。它们甚至可以潜在地恢复患者的正常代谢特征。越来越多的研究人员开始应用代谢组学技术来诊断慢性肝病，并研究有效药物的作用机制或药物反应的变化。我们相信，加深对代谢改变的理解可以扩大它们作为强大生物标志物的用途，促进未来更有效的慢性肝病临床诊断和治疗。越来越多的研究人员开始应用代谢组学技术来诊断慢性肝病，并研究有效药物的作用机制或药物反应的变化。我们相信，加深对代谢改变的理解可以扩大它们作为强大生物标志物的用途，促进未来更有效的慢性肝病临床诊断和治疗。越来越多的研究人员开始应用代谢组学技术来诊断慢性肝病，并研究有效药物的作用机制或药物反应的变化。我们相信，加深对代谢改变的理解可以扩大它们作为强大生物标志物的用途，促进未来更有效的慢性肝病临床诊断和治疗。